169 related articles for article (PubMed ID: 26468877)
21. Theranostic Liposome-Nanoparticle Hybrids for Drug Delivery and Bioimaging.
Seleci M; Ag Seleci D; Scheper T; Stahl F
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671589
[TBL] [Abstract][Full Text] [Related]
22. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma.
Tsui JY; Dalgard C; Van Quill KR; Lee L; Grossniklaus HE; Edelhauser HF; O'Brien JM
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):490-6. PubMed ID: 18234990
[TBL] [Abstract][Full Text] [Related]
23. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
[TBL] [Abstract][Full Text] [Related]
24. Quantification of Unencapsulated Drug in Target Tissues Demonstrates Pharmacological Properties and Therapeutic Effects of Liposomal Topotecan (FF-10850).
Kimura T; Okada K; Morohashi Y; Kato Y; Mori M; Kato H; Matsumoto T; Shimoyama S
Pharm Res; 2024 Apr; 41(4):795-806. PubMed ID: 38536615
[TBL] [Abstract][Full Text] [Related]
25. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
26. Combinational effect of topotecan and octreotide on murine leukemia cells in vivo and in vitro.
Dalezis P; Geromichalos GD; Voyatzi S; Trafalis D; Athanassiou AE; Koutsilieris M; Papageorgiou A
J BUON; 2006; 11(3):323-7. PubMed ID: 17309157
[TBL] [Abstract][Full Text] [Related]
27. Topotecan and doxorubicin combination to treat recurrent ovarian cancer: the influence of drug exposure time and delivery systems to achieve optimum therapeutic activity.
Patankar NA; Pritchard J; van Grinsven M; Osooly M; Bally MB
Clin Cancer Res; 2013 Feb; 19(4):865-77. PubMed ID: 23303216
[TBL] [Abstract][Full Text] [Related]
28. The expression of Bcl-XL, Bcl-XS and p27Kip1 in topotecan-induced apoptosis in hepatoblastoma HepG2 cell line.
Zhang J; Cheng C; He CL; Zhou YJ; Cao Y
Cancer Invest; 2008 Jun; 26(5):456-63. PubMed ID: 18568767
[TBL] [Abstract][Full Text] [Related]
29. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
Subramanian D; Muller MT
Oncol Res; 1995; 7(9):461-9. PubMed ID: 8835290
[TBL] [Abstract][Full Text] [Related]
30. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Rowinsky EK; Adjei A; Donehower RC; Gore SD; Jones RJ; Burke PJ; Cheng YC; Grochow LB; Kaufmann SH
J Clin Oncol; 1994 Oct; 12(10):2193-203. PubMed ID: 7931489
[TBL] [Abstract][Full Text] [Related]
31. Effect of topotecan on retinocytoma cell apoptosis and expression of Livin and PTEN.
Zhang M; Shan BE; Yuan NF; Liu W
Chin Med J (Engl); 2013 Jan; 126(2):340-4. PubMed ID: 23324287
[TBL] [Abstract][Full Text] [Related]
32. Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage.
Tomicic MT; Christmann M; Kaina B
J Pharmacol Exp Ther; 2010 Jan; 332(1):316-25. PubMed ID: 19812371
[TBL] [Abstract][Full Text] [Related]
33. Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice.
Chen J; Lu Q; Balthasar JP
J Pharmacokinet Pharmacodyn; 2007 Dec; 34(6):829-47. PubMed ID: 17885736
[TBL] [Abstract][Full Text] [Related]
34. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
[TBL] [Abstract][Full Text] [Related]
35. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y
J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
O'Reilly S; Fleming GF; Barker SD; Walczak JR; Bookman MA; McGuire WP; Schilder RJ; Alvarez RD; Armstrong DK; Horowitz IR; Ozols RF; Rowinsky EK
J Clin Oncol; 1997 Jan; 15(1):177-86. PubMed ID: 8996140
[TBL] [Abstract][Full Text] [Related]
37. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
Rowinsky EK; Kaufmann SH; Baker SD; Miller CB; Sartorius SE; Bowling MK; Chen TL; Donehower RC; Gore SD
Clin Cancer Res; 1996 Dec; 2(12):1921-30. PubMed ID: 9816150
[TBL] [Abstract][Full Text] [Related]
38. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
39. Chronomodulation of topotecan or X-radiation treatment increases treatment efficacy without enhancing acute toxicity.
Mullins D; Proulx D; Saoudi A; Ng CE
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):230-7. PubMed ID: 15850926
[TBL] [Abstract][Full Text] [Related]
40. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
